BD Secures CE Mark for Adjustable 6–10 mm Liverty™ TIPS Stent Graft in EU
BD secured CE Mark for Liverty™ TIPS Stent Graft, an adjustable-diameter (6–10 mm) device designed to treat portal hypertension and cirrhosis complications across the EU. Pivotal ARCH trial safety and effectiveness data will be unveiled at the SIR Annual Meeting on April 12, 2026.
1. CE Mark Approval
BD obtained CE Mark for the Liverty™ TIPS Stent Graft on April 8, 2026, enabling its use across European Union member states to treat portal hypertension complications in cirrhosis patients.
2. ARCH Clinical Trial Data Presentation
Safety and effectiveness data from the global, prospective ARCH single-arm study will be presented by the trial’s principal investigator on April 12, 2026, at the Society of Interventional Radiology Annual Scientific Meeting.
3. Device Features and Benefits
The Liverty™ TIPS Stent Graft features an adjustable 6–10 mm inner diameter, a flexible self-expanding nitinol frame and dual-layer ePTFE encapsulation with carbon impregnation, delivered via a triaxial system for precise placement.
4. EU Commercial Outlook
With CE Mark clearance secured, BD plans to roll out the Liverty™ TIPS Stent Graft commercially across EU markets, strengthening its interventional portfolio for advanced liver disease therapies.